Skip to content
Screener

Net Change in Cash at other companies

Pfizer logo
PfizerPFE
$563M+50.1%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$4.04M-4,386%
AbbVie logo
AbbVieABBV
$4.16B+1,293%
Immunome logo
ImmunomeIMNM
-$70.79M-162%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$51M-191%
CTO
Citius Oncology, Inc.CTOR
-$4.66M-575%

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$2.3B+1,350%
Enterprise value$2.19B+1,537%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0.0×
Current ratio17.2×+12.6×

Where this comes from

Reported directly by SELLAS Life Sciences Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001390478-26-000008
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs23,030
Proceeds from employee stock purchases6648
Net cash provided by financing activities44,15023,581
Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents35,30414,511
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period71,89313,986
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period$107,197$28,497
Supplemental disclosure of cash flow information:
Cash received during the period for interest$845$250

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is SELLAS Life Sciences Group, Inc.'s net change in cash?
SELLAS Life Sciences Group, Inc. (SLS) reported net change in cash of $35.3M in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s net change in cash changed year-over-year?
SELLAS Life Sciences Group, Inc.'s net change in cash increased by 143.3% year-over-year, from $14.51M to $35.3M.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s net change in cash?
Over 2 years (2022 to 2025), SELLAS Life Sciences Group, Inc.'s net change in cash has grown at a 279.8% compound annual growth rate (CAGR), from -$4.23M to $61.01M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about SELLAS Life Sciences Group, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude